Brought to you by:
New analysis probes BEST-CLI trial against real-world setting data
A new analysis of chronic limb-threatening ischemia (CLTI) treatment outcomes was presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions (May 18–20) in Phoenix. Since the initial results of the BEST-CLI trial found surgery superior to…
The Big Interview: Pioneering surgeon recounts career as new VAM lectureship is birthed
Vascular Specialist medical editor Malachi Sheahan III, MD, sits down with Frank J. Veith, MD, to discuss his new book, The Medical Jungle, ahead of the maiden named Vascular Annual Meeting (VAM) lecture created in the former SVS President’s honor. The Frank…
Frailty status beats WIfI score as mortality predictor in all-comer CLTI study
A study presented during Plenary Session 3 at last week’s Vascular Annual Meeting (VAM), concluded that the Wound, Ischemia, and Foot Infection (WIfI) stage is predictive of major amputation at one-year follow-up in patients with chronic limb-threatening ischemia (CLTI), while…
BEST-CLI investigators implore a move beyond endo vs. open ‘battle’ in the name of scientific advance
The principal investigators behind the BEST-CLI trial struck a conciliatory tone during the inaugural Frank J. Veith Distinguished Lecture yesterday morning in which they laid bare the blood, sweat and tears shed on their journey to complete the landmark study.…
Special VAM session underscores ‘complementary’ nature of open and endovascular strategies in CLTI patients
A dedicated session at VAM 2023 saw speakers and delegates gather to debate, analyse and consider the implementation of the BEST-CLI and BASIL-2 randomized-controlled trials (RCTs). There was general agreement that the strategies are complementary, and that “picking the right…
The global burden of CLTI: ESVS President points toward need for new global vascular guidelines
Early-bird VAM 2023 attendees yesterday gained broad insight into the issues facing vascular surgeons around the world, with the tone set from the opening talk on the World Federation of Vascular Societies (WFVS) Educational Session docket. Looking at the global…
BEST-CLI vs. BASIL-2: Different questions yield different answers
Medical editor Malachi Sheahan III, MD, takes a look at seemingly conflicting results from the landmark BEST-CLI and BASIL-2 trials, and asks what they really reveal. This past April, BASIL-2 chief investigator Andrew Bradbury, MD, presented trial results at the…
BASIL-2 and BEST-CLI: A tale of two limb trials
Optimal treatment of patients with chronic limb-threatening ischemia (CLTI) has been an ongoing debate within the vascular community, fueled by growing numbers of patients, evolving technologies, provider bias, and a lack of high-quality evidence. Few randomized controlled trials (RCTs) have…
Urban residents have smaller risk of mortality from chronic limb-threatening ischemia
A new study using data from millions of patients hospitalized across the U.S. has determined whether population density and associated urban versus suburban versus rural environments predispose patients with peripheral vascular disease for chronic poor blood flow in their lower…
Insights from largest chronic limb-threatening ischaemia study to inform quality of care improvements
Data from a cohort of one million patients with chronic limb-threatening ischaemia (CLTI) were recently presented as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions (18–20 May, Phoenix, USA). Using data from Medicare, the…